• In early April 2026, Anthropic, Genentech, IBM, Meta, Microsoft, and others launched the Shared AI License Foundation and IBM expanded its AI, quantum, and hardware collaborations, while also securing FedRAMP authorization for 11 watsonx and automation tools and settling a US$17,000,000 U.S. DEI probe.
• Together, these moves underline IBM’s push to position itself at the center of open, enterprise-grade AI and quantum infrastructure while addressing regulatory scrutiny.
• We’ll now explore how IBM’s role in the Shared AI License Foundation may reshape its investment narrative around AI and quantum leadership.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

International Business Machines Investment Narrative Recap

To own IBM today, you need to believe its pivot around hybrid cloud, AI and mission‑critical infrastructure can offset pressure on legacy software and consulting demand. Near term, the key catalyst is execution on AI and mainframe adoption, while the biggest risk remains macro‑driven softness in consumption‑based Software and Consulting. The latest AI, quantum and hardware announcements, along with the US$17,000,000 DEI settlement, do not fundamentally alter these short‑term drivers but do sharpen the regulatory and reputational backdrop.

The most relevant update here is IBM joining Anthropic, Genentech, Meta, Microsoft and others in the new Shared AI License Foundation. For shareholders focused on AI and quantum as core catalysts, this collaborative patent network directly intersects IBM’s ambition to be an enterprise‑grade AI infrastructure provider, reinforcing its watsonx, mainframe and quantum efforts while potentially broadening the ecosystem that sits around those platforms.

Yet while IBM is leaning into open, enterprise AI, investors should also be aware of the growing tension between open ecosystems and the risk that...

International Business Machines' narrative projects $74.4 billion revenue and $10.5 billion earnings by 2028. This requires 5.1% yearly revenue growth and an earnings increase of about $4.6 billion from $5.9 billion today.

Uncover how International Business Machines' forecasts yield a $302.05 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most optimistic analysts were already modeling IBM revenue at about US$80.3 billion and earnings of roughly US$14.3 billion, and they see announcements like SAIL as potential fuel for that story, even as the risk that open source erodes IBM’s proprietary software economics reminds you that smart people can disagree and your own view should sit somewhere along this wide spectrum.

Explore 13 other fair value estimates on International Business Machines - why the stock might be worth just $223.21!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your International Business Machines research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free International Business Machines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate International Business Machines' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.